Cheng Guangyu, Li Lin, Li Qingjie, Lian Shulin, Chu Hongbo, Ding Yunlu, Li Chikun, Leng Yan
Research Center, Affiliated Hospital to Changchun University of Chinese Medicine Jilin 130021, China.
Department of Health Care, Affiliated Hospital to Changchun University of Chinese Medicine Jilin 130021, China.
Am J Cancer Res. 2022 Apr 15;12(4):1535-1555. eCollection 2022.
Multi-drug resistance remains a critical issue in cancer treatment that hinders the effective use of chemotherapeutic drugs. The active components of traditional Chinese medicine have been applied as adjuvants to accentuate the anticancer properties of conventional drugs such as cisplatin. However, their application requires further validation and optimization. This study explored the anticancer activity of β-elemene, a natural component of traditional Chinese medical formulations. The effect of β-elemene on the anticancer properties of cisplatin was evaluated in A549 and NCI-H1650 lung cancer cells. Cell apoptosis, stem-like properties, glucose metabolism, multi-drug resistance, and PI3K/AKT/mTOR activation were assessed via flow cytometry, tumorsphere formation, and western blotting. The target genes of β-elemene were predicted using bioinformatics tools and validated in both cell lines. A xenograft model of lung cancer was established in nude mice to evaluate the combined effects of β-elemene and cisplatin . We found that β-elemene acted synergistically with cisplatin against non-small cell lung cancer cells by promoting apoptosis and impairing glucose metabolism, multi-drug resistance, and stemness maintenance. These effects were mediated by the inhibition of PI3K/AKT/mTOR activation. Bioinformatics analysis revealed that RB1 and TP53 are common target genes associated with lung cancer and β-elemene. The anti-tumorigenic properties of β-elemene were confirmed , wherein β-elemene, along with cisplatin, significantly suppressed tumor growth in a mouse xenograft model of non-small cell lung cancer. As such, β-elemene acted as an inhibitor of PI3K/AKT/mTOR signaling and enhanced the anticancer effect of cisplatin by targeting tumor metabolism, chemoresistance, and stem-like behavior. Thus, β-elemene is an effective anticancer adjuvant agent with potential clinical applications.
多药耐药性仍然是癌症治疗中的一个关键问题,它阻碍了化疗药物的有效使用。中药的活性成分已被用作佐剂,以增强顺铂等传统药物的抗癌特性。然而,它们的应用需要进一步验证和优化。本研究探讨了中药制剂中的天然成分β-榄香烯的抗癌活性。在A549和NCI-H1650肺癌细胞中评估了β-榄香烯对顺铂抗癌特性的影响。通过流式细胞术、肿瘤球形成和蛋白质印迹法评估细胞凋亡、干细胞样特性、葡萄糖代谢、多药耐药性和PI3K/AKT/mTOR激活。使用生物信息学工具预测β-榄香烯的靶基因,并在两种细胞系中进行验证。在裸鼠中建立肺癌异种移植模型,以评估β-榄香烯和顺铂的联合作用。我们发现,β-榄香烯通过促进细胞凋亡和损害葡萄糖代谢、多药耐药性和干性维持,与顺铂协同作用对抗非小细胞肺癌细胞。这些作用是由PI3K/AKT/mTOR激活的抑制介导的。生物信息学分析表明,RB1和TP53是与肺癌和β-榄香烯相关的共同靶基因。β-榄香烯的抗肿瘤特性得到证实,其中β-榄香烯与顺铂一起,在非小细胞肺癌小鼠异种移植模型中显著抑制肿瘤生长。因此,β-榄香烯作为PI3K/AKT/mTOR信号的抑制剂,通过靶向肿瘤代谢、化疗耐药性和干细胞样行为增强了顺铂的抗癌效果。因此,β-榄香烯是一种具有潜在临床应用价值的有效抗癌佐剂。